A Phase 4 interventional study of Vedolizumab IV in Ulcerative Colitis and Crohn Disease, sponsored by Takeda. Completed at 17 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-12.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 16th largest by enrollment, is one of 5 that started in 2021, is one of 15 in phase 4, and was the 28th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 26th largest by enrollment of the 43 interventional ones that give a count, is one of 9 that started in 2021, is one of 9 in phase 4, and was the 48th registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, people with ulcerative colitis or Crohn's disease will be treated with vedolizumab. The main aim of the study is to check for side effects from vedolizumab.
At the first visit, the study doctor will check who can take part. Participants will receive vedolizumab slowly through a vein (infusion). Participants will regularly visit the clinic for up to 46 weeks for more infusions of Vedolizumab. During these visits, the study doctor will check if there are any side effects from this treatment.
Participants will visit the clinic for a final check-up up to 16 weeks after their final infusion of Vedolizumab. Clinic staff will arrange a phone call 6 months after their final infusion of Vedolizumab for a further check-up.
The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who have active UC or CD.
The study will enroll approximately 150 patients. Participants will be assigned to the vedolizumab treatment group.
•Vedolizumab 300 mg
Vedolizumab 300 mg IV infusion will be administered once in Weeks 0, 2, 6 and 10 (CD-participants who have not shown a response can receive a dose at Week 10) during induction phase and in Weeks 14, 22, 30, 38 and 46 during maintenance phase.
This multicentre trial will be conducted in India. The overall time to participate in this study is 74 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone plus a final visit after receiving their last dose of drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has demonstrated, an inadequate response to, loss of response to, or intolerance to at least 1 of the following agents:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab 300 mg IV infusion will be administered once in Weeks 0, 2 and 6 during induction phase and in Weeks 14, 22, 30, 38 and 46 during maintenance phase.
Drug: Vedolizumab IV
Vedolizumab IV infusion
Also known as: Kynteles
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
AE was defined as any untoward medical occurrence in clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with the treatment. AE can therefore be any unfavourable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with use of a drug, whether or not it is considered related to the drug. A SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in significant disability or incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI (serious or nonserious) was one of scientific and medical concern specific to the compound or program.
Time frame: From first dose of study drug up to 24 weeks after the last dose (up to 70 weeks)
Number of Participants With Adverse Drug Reactions (ADRs) and Unexpected ADRs
An ADR was an AE for which there was at least a reasonable suspicion of a causal relationship between an AE and a suspected medicinal product. An unexpected ADR was an ADR with the nature, severity, or outcome which was not consistent with the product insert.
Time frame: From first dose of study drug up to 24 weeks after the last dose (up to 70 weeks)
Percentage of UC Participants With Clinical Response at Weeks 14, 30 and 46
Clinical response for UC participants was defined as decrease in Simple Clinical Colitis Activity Index (SCCAI) of greater than and equal to (\>=) 3 from baseline or by physician assessment of clinical response. The SCCAI consists of five colitis activity symptom items (bowel frequency per day, bowel frequency per night, urgency of defecation, blood in stool, and general well-being) along with an assessment of extracolonic manifestations. Bowel frequency per night is scored on a 0-2 scale and General well-being is scored on a 0-4 scale. The other 3 symptom scores are scored on a 0-3 scale. 1 point each is added for the presence of any extracolonic manifestation (i.e., arthritis, erythema nodosum, pyoderma gangrenosum, and uveitis). The total overall possible scoring range was 0-19 with increasing scores being indicative of more colitis activity.
Time frame: At Weeks 14, 30 and 46
Percentage of CD Participants With Clinical Response at Weeks 14, 30 and 46
Clinical response for CD participants was defined as decrease in Harvey Bradshaw Index (HBI) of \>= 3 points from baseline. HBI was composed of five clinical parameters: general well-being (0-4, where higher score means lower wellbeing), abdominal pain (0-3, higher score means more severe pain), number of liquid stools/day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score was the sum of individual parameters. The score ranged from a minimum score of 0 to no pre-specified maximum score as it depended on the number of liquid stools, where higher scores indicated more severe disease. The score \< 5 is considered as clinical remission, 5-7 mild, 8-16 moderate, and \>16 severe disease. A higher score indicated a worse outcome.
Time frame: At Weeks 14, 30 and 46
Percentage of UC Participants With Clinical Remission at Weeks 14, 30 and 46
Clinical remission for UC participants was defined as decrease in SCCAI of less than and equal to (\<=) 2 with no individual score \> 1. The SCCAI consists of five colitis activity symptom items (bowel frequency per day, bowel frequency per night, urgency of defecation, blood in stool, and general well-being) along with an assessment of extracolonic manifestations. Bowel frequency per night is scored on a 0-2 scale and General well-being is scored on a 0-4 scale. The other 3 symptom scores are scored on a 0-3 scale. 1 point each is added for the presence of any extracolonic manifestation (i.e., arthritis, erythema nodosum, pyoderma gangrenosum, and uveitis). The total overall possible scoring range was 0-19 with increasing scores being indicative of more colitis activity.
Time frame: At Weeks 14, 30 and 46
Percentage of CD Participants With Clinical Remission at Weeks 14, 30 and 46
Clinical remission for CD participants was defined as HBI of \<= 4. HBI was composed of five clinical parameters: general well-being (0-4, where higher score means lower wellbeing), abdominal pain (0-3, higher score means more severe pain), number of liquid stools/day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score was the sum of individual parameters. The score ranged from a minimum score of 0 to no pre-specified maximum score as it depended on the number of liquid stools, where higher scores indicated more severe disease. The score \< 5 is considered as clinical remission, 5-7 mild, 8-16 moderate, and \>16 severe disease. A higher score indicated a worse outcome.
Time frame: At Weeks 14, 30 and 46
Percentage of UC and CD Participants Who Discontinued Vedolizumab
Vedolizumab discontinuation was defined as ceasing vedolizumab, or a treatment gap \>= 90 days between consecutive doses.
Time frame: From first dose of study drug up to Week 46
Percentage of UC Participants With Mucosal Healing at Week 46
Mucosal healing was based on endoscopic evidence of no inflammation and healing of the mucosa as defined by a Mayo endoscopic sub-score of \<=1 point. Full Mayo Score evaluated ulcerative colitis stage, based on four parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician's global assessment. Each parameter of the score (including Mayo endoscopic sub-score) ranged from 0 (normal or inactive disease) to 3 (severe activity) yielding a total score of 0-12. The scores 0-2 were considered as clinical remission, 3-5 mild, 6-10 moderate, and 11-12 severe, with higher scores indicated more severe disease.
Time frame: At Week 46
Percentage of CD Participants With Mucosal Healing at Week 46
Mucosal healing was based on endoscopic evidence of no inflammation and healing of the mucosa as defined by a Simple Endoscopic Score for Crohn Disease (SES-CD) 0-2 or SES-CD \<=4 and at least a 2-point reduction from baseline with no sub-score \>1. SES-CD assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension, and the presence and type of narrowings. Each of the four SES-CD variables was scored from 0 to 3, with the sum of scores for each variable ranging from 0 to 15 yielding a total SES-CD score of 0-60, where higher scores indicated more severe disease.
Time frame: At Week 46
Percentage of UC Participants With Endoscopic Response at Week 46
Endoscopic response was defined as decrease in Mayo endoscopic sub-score of \>=1 point in UC participants. Full Mayo Score evaluated ulcerative colitis stage, based on four parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician's global assessment. Each parameter of the score (including Mayo endoscopic sub-score) ranges from 0 (normal or inactive disease) to 3 (severe activity) yielding a total score of 0-12. The scores 0-2 are considered as clinical remission, 3-5 mild, 6-10 moderate, and 11-12 severe, where higher scores indicated more severe disease.
Time frame: At Week 46
Percentage of CD Participants With Endoscopic Response at Week 46
Endoscopic response was defined as \> 50% decrease in SES-CD in CD participants. SES-CD assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension, and the presence and type of narrowings. Each of the four SES-CD variables was scored from 0 to 3, with the sum of scores for each variable ranged from 0 to 15 yielding a total SES-CD score of 0-60, where higher scores indicated more severe disease.
Time frame: At Week 46
Change From Baseline in Patient-reported Quality of Life (Short Inflammatory Bowel Disease Questionnaire [SIBDQ]) Scores at Weeks 14, 30, and 46
The SIBDQ was a valid and reliable instrument used to assess quality of life in adult participants with Inflammatory Bowel Disease (IBD). It was a 10-item questionnaire that included questions on 4 domains of health-related quality of life (HRQoL): bowel systems, emotional function, social function, and systemic function and was scored on a 7-point Likert scale from 1 (severe problem) to 7 (no problems at all). A total SIBDQ score was calculated by summing the scores from each domain; the total SIBDQ score ranged from 10 (poor HRQoL) to 70 (optimum HRQoL). Higher values of SIBDQ represented a better quality of life.
Time frame: Baseline, Weeks 14, 30 and 46
Participants took part in the study at the 17 investigative sites in India from 08 December 2021 to 02 February 2024.
| Milestone | UC Participants: Vedolizumab 300 mg | CD Participants: Vedolizumab 300 mg |
|---|---|---|
| Started | 102 | 48 |
| Completed | 76 | 35 |
| Not completed | 26 | 13 |
| Withdrew: Adverse event | 26 | 13 |
AE was defined as any untoward medical occurrence in clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with the treatment. AE can therefore be any unfavourable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with use of a drug, whether or not it is considered related to the drug. A SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in significant disability or incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI (serious or nonserious) was one of scientific and medical concern specific to the compound or program.
| Participants | UC Participants: Vedolizumab 300 mg | CD Participants: Vedolizumab 300 mg |
|---|---|---|
| Participants with AEs | 54 | 29 |
| Participants with SAEs | 6 | 2 |
| Participants with AESIs | 4 | 0 |
An ADR was an AE for which there was at least a reasonable suspicion of a causal relationship between an AE and a suspected medicinal product. An unexpected ADR was an ADR with the nature, severity, or outcome which was not consistent with the product insert.
| Participants | UC Participants: Vedolizumab 300 mg | CD Participants: Vedolizumab 300 mg |
|---|---|---|
| Participants with ADRs | 5 | 0 |
| Participants with Unexpected ADRs | 2 | 0 |
Clinical response for UC participants was defined as decrease in Simple Clinical Colitis Activity Index (SCCAI) of greater than and equal to (\>=) 3 from baseline or by physician assessment of clinical response. The SCCAI consists of five colitis activity symptom items (bowel frequency per day, bowel frequency per night, urgency of defecation, blood in stool, and general well-being) along with an assessment of extracolonic manifestations. Bowel frequency per night is scored on a 0-2 scale and General well-being is scored on a 0-4 scale. The other 3 symptom scores are scored on a 0-3 scale. 1 point each is added for the presence of any extracolonic manifestation (i.e., arthritis, erythema nodosum, pyoderma gangrenosum, and uveitis). The total overall possible scoring range was 0-19 with increasing scores being indicative of more colitis activity.
| percentage of participants | UC Participants: Vedolizumab 300 mg |
|---|---|
| At Week 14 | 54.9 (44.7 to 64.8) |
| At Week 30 | 62.7 (52.6 to 72.1) |
| At Week 46 | 73.5 (63.9 to 81.8) |
Clinical response for CD participants was defined as decrease in Harvey Bradshaw Index (HBI) of \>= 3 points from baseline. HBI was composed of five clinical parameters: general well-being (0-4, where higher score means lower wellbeing), abdominal pain (0-3, higher score means more severe pain), number of liquid stools/day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score was the sum of individual parameters. The score ranged from a minimum score of 0 to no pre-specified maximum score as it depended on the number of liquid stools, where higher scores indicated more severe disease. The score \< 5 is considered as clinical remission, 5-7 mild, 8-16 moderate, and \>16 severe disease. A higher score indicated a worse outcome.
| percentage of participants | CD Participants: Vedolizumab 300 mg |
|---|---|
| At Week 14 | 72.9 (58.2 to 84.7) |
| At Week 30 | 70.8 (55.9 to 83.0) |
| At Week 46 | 68.8 (53.7 to 81.3) |
Clinical remission for UC participants was defined as decrease in SCCAI of less than and equal to (\<=) 2 with no individual score \> 1. The SCCAI consists of five colitis activity symptom items (bowel frequency per day, bowel frequency per night, urgency of defecation, blood in stool, and general well-being) along with an assessment of extracolonic manifestations. Bowel frequency per night is scored on a 0-2 scale and General well-being is scored on a 0-4 scale. The other 3 symptom scores are scored on a 0-3 scale. 1 point each is added for the presence of any extracolonic manifestation (i.e., arthritis, erythema nodosum, pyoderma gangrenosum, and uveitis). The total overall possible scoring range was 0-19 with increasing scores being indicative of more colitis activity.
| percentage of participants | UC Participants: Vedolizumab 300 mg |
|---|---|
| At Week 14 | 39.2 (29.7 to 49.4) |
| At Week 30 | 43.1 (33.4 to 53.3) |
| At Week 46 | 52.0 (41.8 to 62.0) |
Clinical remission for CD participants was defined as HBI of \<= 4. HBI was composed of five clinical parameters: general well-being (0-4, where higher score means lower wellbeing), abdominal pain (0-3, higher score means more severe pain), number of liquid stools/day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score was the sum of individual parameters. The score ranged from a minimum score of 0 to no pre-specified maximum score as it depended on the number of liquid stools, where higher scores indicated more severe disease. The score \< 5 is considered as clinical remission, 5-7 mild, 8-16 moderate, and \>16 severe disease. A higher score indicated a worse outcome.
| percentage of participants | CD Participants: Vedolizumab 300 mg |
|---|---|
| At Week 14 | 47.9 (33.3 to 62.8) |
| At Week 30 | 45.8 (31.4 to 60.8) |
| At Week 46 | 56.3 (41.2 to 70.5) |
Vedolizumab discontinuation was defined as ceasing vedolizumab, or a treatment gap \>= 90 days between consecutive doses.
| percentage of participants | UC Participants: Vedolizumab 300 mg | CD Participants: Vedolizumab 300 mg |
|---|---|---|
| Percentage of UC and CD Participants Who Discontinued Vedolizumab | 25.5 (17.4 to 35.1) | 27.1 (15.3 to 41.8) |
Mucosal healing was based on endoscopic evidence of no inflammation and healing of the mucosa as defined by a Mayo endoscopic sub-score of \<=1 point. Full Mayo Score evaluated ulcerative colitis stage, based on four parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician's global assessment. Each parameter of the score (including Mayo endoscopic sub-score) ranged from 0 (normal or inactive disease) to 3 (severe activity) yielding a total score of 0-12. The scores 0-2 were considered as clinical remission, 3-5 mild, 6-10 moderate, and 11-12 severe, with higher scores indicated more severe disease.
| percentage of participants | UC Participants: Vedolizumab 300 mg |
|---|---|
| Percentage of UC Participants With Mucosal Healing at Week 46 | 22.5 (14.9 to 31.9) |
Mucosal healing was based on endoscopic evidence of no inflammation and healing of the mucosa as defined by a Simple Endoscopic Score for Crohn Disease (SES-CD) 0-2 or SES-CD \<=4 and at least a 2-point reduction from baseline with no sub-score \>1. SES-CD assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension, and the presence and type of narrowings. Each of the four SES-CD variables was scored from 0 to 3, with the sum of scores for each variable ranging from 0 to 15 yielding a total SES-CD score of 0-60, where higher scores indicated more severe disease.
| percentage of participants | CD Participants: Vedolizumab 300 mg |
|---|---|
| Percentage of CD Participants With Mucosal Healing at Week 46 | 8.3 (2.3 to 20.0) |
Endoscopic response was defined as decrease in Mayo endoscopic sub-score of \>=1 point in UC participants. Full Mayo Score evaluated ulcerative colitis stage, based on four parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician's global assessment. Each parameter of the score (including Mayo endoscopic sub-score) ranges from 0 (normal or inactive disease) to 3 (severe activity) yielding a total score of 0-12. The scores 0-2 are considered as clinical remission, 3-5 mild, 6-10 moderate, and 11-12 severe, where higher scores indicated more severe disease.
| percentage of participants | UC Participants: Vedolizumab 300 mg |
|---|---|
| Percentage of UC Participants With Endoscopic Response at Week 46 | 21.6 (14.0 to 30.8) |
Endoscopic response was defined as \> 50% decrease in SES-CD in CD participants. SES-CD assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension, and the presence and type of narrowings. Each of the four SES-CD variables was scored from 0 to 3, with the sum of scores for each variable ranged from 0 to 15 yielding a total SES-CD score of 0-60, where higher scores indicated more severe disease.
| percentage of participants | CD Participants: Vedolizumab 300 mg |
|---|---|
| Percentage of CD Participants With Endoscopic Response at Week 46 | 12.5 (4.7 to 25.2) |
The SIBDQ was a valid and reliable instrument used to assess quality of life in adult participants with Inflammatory Bowel Disease (IBD). It was a 10-item questionnaire that included questions on 4 domains of health-related quality of life (HRQoL): bowel systems, emotional function, social function, and systemic function and was scored on a 7-point Likert scale from 1 (severe problem) to 7 (no problems at all). A total SIBDQ score was calculated by summing the scores from each domain; the total SIBDQ score ranged from 10 (poor HRQoL) to 70 (optimum HRQoL). Higher values of SIBDQ represented a better quality of life.
| score on a scale | UC Participants: Vedolizumab 300 mg | CD Participants: Vedolizumab 300 mg |
|---|---|---|
| Change at Week 14 | 8.4 ± 12.91 | 8.3 ± 12.24 |
| Change at Week 30 | 12.9 ± 13.16 | 8.4 ± 14.31 |
| Change at Week 46 | 13.0 ± 12.84 | 10.6 ± 15.91 |
Collected over From first dose of study drug up to 24 weeks after the last dose (up to 70 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| UC Participants: Vedolizumab 300 mg | 0/102 (0%) | 6/102 (5.9%) | 25/102 (24.5%) |
| CD Participants: Vedolizumab 300 mg | 0/48 (0%) | 2/48 (4.2%) | 19/48 (39.6%) |
| Event | UC Participants: Vedolizumab 300 mg | CD Participants: Vedolizumab 300 mg |
|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 0/102 | 1/48 |
| Small intestinal obstructionGastrointestinal disorders | 1/102 | 1/48 |
| CholelithiasisHepatobiliary disorders | 1/102 | 0/48 |
| Colitis ulcerativeGastrointestinal disorders | 1/102 | 0/48 |
| Pulmonary tuberculosisInfections and infestations | 1/102 | 0/48 |
| Rectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/102 | 0/48 |
| Tuberculous pleurisyInfections and infestations | 1/102 | 0/48 |
| Event | UC Participants: Vedolizumab 300 mg | CD Participants: Vedolizumab 300 mg |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 8/102 | 6/48 |
| PyrexiaGeneral disorders | 7/102 | 6/48 |
| HeadacheNervous system disorders | 5/102 | 4/48 |
| VomitingGastrointestinal disorders | 0/102 | 4/48 |
| Colitis ulcerativeGastrointestinal disorders | 7/102 | 0/48 |
| Aphthous ulcerGastrointestinal disorders | 0/102 | 3/48 |
| DizzinessNervous system disorders | 3/102 | 3/48 |
The Safety Analysis Set (SAS) included all enrolled participants who received at least 1 dose of study drug.
| Age, Continuous(years) | UC Participants: Vedolizumab 300 mg | CD Participants: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 38.55 ± 11.190 | 32.60 ± 10.849 | 36.65 ± 11.391 |
| Sex: Female, Male(Participants) | UC Participants: Vedolizumab 300 mg | CD Participants: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Female | 35 | 32 | 67 |
| Male | 67 | 16 | 83 |
| Race/Ethnicity, Customized(Participants) | UC Participants: Vedolizumab 300 mg | CD Participants: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Race — Indian | 102 | 48 | 150 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Dec 2021 to primary completion in Feb 2024, 25 months.
Results were first posted in Feb 2025, 1 year after primary completion.
Of 63 phase 4 interventional studies under Colitis, Ulcerative, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 63. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab